Public Employees Retirement System of Ohio Buys 543 Shares of Ultragenyx Pharmaceutical Inc. $RARE

Public Employees Retirement System of Ohio raised its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 2.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 27,885 shares of the biopharmaceutical company’s stock after acquiring an additional 543 shares during the period. Public Employees Retirement System of Ohio’s holdings in Ultragenyx Pharmaceutical were worth $1,014,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. GAMMA Investing LLC grew its position in Ultragenyx Pharmaceutical by 76.2% during the first quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 323 shares during the last quarter. Parallel Advisors LLC grew its position in Ultragenyx Pharmaceutical by 1,061.9% during the second quarter. Parallel Advisors LLC now owns 732 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 669 shares during the last quarter. ANTIPODES PARTNERS Ltd bought a new position in Ultragenyx Pharmaceutical during the first quarter valued at approximately $57,000. Headlands Technologies LLC bought a new position in Ultragenyx Pharmaceutical during the first quarter valued at approximately $59,000. Finally, Covestor Ltd grew its position in Ultragenyx Pharmaceutical by 86.8% during the first quarter. Covestor Ltd now owns 1,711 shares of the biopharmaceutical company’s stock valued at $62,000 after acquiring an additional 795 shares during the last quarter. 97.67% of the stock is currently owned by institutional investors.

Ultragenyx Pharmaceutical Trading Up 1.0%

Shares of Ultragenyx Pharmaceutical stock opened at $31.21 on Friday. The firm has a market capitalization of $3.01 billion, a P/E ratio of -5.64 and a beta of 0.21. The business has a fifty day simple moving average of $29.44 and a two-hundred day simple moving average of $33.30. Ultragenyx Pharmaceutical Inc. has a 12 month low of $25.81 and a 12 month high of $57.99.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.27) by $0.10. The firm had revenue of $166.50 million during the quarter, compared to analyst estimates of $161.37 million. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.Ultragenyx Pharmaceutical’s quarterly revenue was up 13.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.52) EPS. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. Analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on RARE shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $105.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Friday, September 5th. Canaccord Genuity Group reduced their price target on shares of Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. HC Wainwright reiterated a “buy” rating and set a $80.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, September 9th. Morgan Stanley dropped their price objective on Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an “overweight” rating for the company in a research note on Monday, July 14th. Finally, Wedbush dropped their price objective on Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a “neutral” rating for the company in a research note on Monday, July 14th. Eleven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Ultragenyx Pharmaceutical has a consensus rating of “Moderate Buy” and an average target price of $81.50.

Insider Activity

In other news, EVP Karah Herdman Parschauer sold 2,450 shares of Ultragenyx Pharmaceutical stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $31.17, for a total value of $76,366.50. Following the completion of the transaction, the executive vice president owned 73,271 shares of the company’s stock, valued at $2,283,857.07. The trade was a 3.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 5.50% of the stock is currently owned by corporate insiders.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.